| gap-pubmed-20260410- | How can NRF1 be therapeutically targeted without disrupting essential mitochondr | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines tissue-specific vulnerability to NRF1-mediated inflammaging acro | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does NRF1's dual role in mitochondrial biogenesis versus innate immunity cre | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do oncogenes co-opt SWI/SNF function to drive transformation in neural tissu | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | What mechanisms link SWI/SNF mutations to neurodevelopmental disorders versus ca | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What determines HACE1's transition from tumor suppressor to neurodegeneration me | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does HACE1 substrate specificity determine disease-specific pathology in dif | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines synapse selectivity in complement-dependent microglial phagocyto | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does caspase-3 activation facilitate complement tagging at synapses without | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms trigger activity-dependent, nonapoptotic caspase-3 act | open | 0.80 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What is the molecular mechanism by which TMEM106B modifies FTLD-GRN disease risk | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Which non-coding genetic variants in linkage disequilibrium with rs3173615 media | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does the protective TMEM106B T185S variant fail to show protection in mouse | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does TFAM-mediated autophagy of cytoplasmic mtDNA specifically limit neuroin | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines TFAM's selectivity for cytoplasmic versus mitochondrial mtDNA bi | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does Miro1 dysfunction occur in skin fibroblasts when PD primarily affects d | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the identified small molecule repair Miro1 defects and what are its mol | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanism causes >94% of PD patients to fail Miro1 removal from d | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does BIN1 expression and function in microglia compare to its well-character | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does bone-specific autophagy disruption relate to neurodegeneration in envir | open | 0.72 | 0.00 | 2026-04-10 | 0 | | environmental-neurotoxicology |
| gap-pubmed-20260410- | Why does AKT1 upregulation correlate with suppressed autophagy when AKT1 typical | open | 0.80 | 0.00 | 2026-04-10 | 0 | | cellular-neurobiology |
| gap-pubmed-20260410- | What mechanisms explain IVIg's protective effect against respiratory infections | open | 0.70 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why did IVIg selectively reduce plasma Aβ42 but not Aβ40 levels despite showing | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the temporal dynamics and reversibility of heat stress-induced neurobiol | open | 0.76 | 0.00 | 2026-04-10 | 0 | | stress-neurobiology |
| gap-pubmed-20260410- | How do individual differences in stress susceptibility affect heat-induced anxie | open | 0.80 | 0.00 | 2026-04-10 | 0 | | stress-neurobiology |
| gap-pubmed-20260410- | What are the specific molecular mechanisms linking HPA axis activation to neurot | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroendocrinology |
| gap-pubmed-20260410- | How can therapeutic targeting overcome current challenges in cGAS/STING modulato | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms determine context-dependent pro- vs anti-oncogenic rol | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does OX2R C-terminal dysfunction contribute to depression and anorexia patho | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuropsychiatry |
| gap-pubmed-20260410- | What molecular mechanisms underlie the differential functional roles of distinct | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroscience |
| gap-pubmed-20260410- | How does LRRK2 kinase activity specifically regulate MiT-TFE factors - through d | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does LRRK2-mediated lysosomal suppression contribute to alpha-synuclein accumula | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the molecular mechanism by which LRRK2 controls MiT-TFE transcription fa | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the optimal treatment duration and dosing regimen for QZP in facial nerv | open | 0.72 | 0.00 | 2026-04-10 | 0 | | peripheral-nerve-regeneration |
| gap-pubmed-20260410- | How does QZP treatment compare to established BDNF-based therapies for periphera | open | 0.75 | 0.00 | 2026-04-10 | 0 | | peripheral-nerve-regeneration |
| gap-pubmed-20260410- | Which specific bioactive compounds in QZP are responsible for BDNF/TrkB/CREB pat | open | 0.80 | 0.00 | 2026-04-10 | 0 | | peripheral-nerve-regeneration |
| gap-pubmed-20260410- | How do conditioning regimens and GVHD specifically contribute to neurological co | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms underlie the high incidence of neurological effects (9.4%) after | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the ER stress-UPR pathway specifically lead to neuronal vulnerability i | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link GBA1 mutations to ER calcium homeostasis impairme | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can genotype-stratified therapeutics targeting common ALS pathways be effect | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the complete genetic causes of ALS beyond the currently identified gene | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do the seven novel ALS genes function in animal models to cause neurodegener | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does chemerin-CMKLR1 signaling coordinate mitochondrial dynamics with autoph | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms drive opposite chemerin expression patterns in microgl | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do monoamine disruptions, glutamatergic dysfunction, and neuroinflammation i | open | 0.76 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What are the specific molecular mechanisms linking AD pathophysiology to depress | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do plasma levels of synaptic and vascular proteins relate to their brain tis | open | 0.79 | 0.00 | 2026-04-10 | 0 | | biomarker-validation |
| gap-pubmed-20260410- | What mechanisms drive the temporal sequence of inflammatory marker changes in pr | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do multiple biomarkers decrease rather than increase with amyloid pathology | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |